BACKGROUND: Transforming growth factor-β1 (TGF-β1) may be implicated in the development of Chagas heart disease. However, the clinical value of TGF-β1 measurement is yet to be determined. METHODS: We retrospectively analyzed the outcome of 54 Chagas disease patients without heart failure and with left ventricular (LV) ejection fraction >45% whose TGF-β1 serum values were determined between January 1998 and December 1999. Primary end point was all-cause mortality and secondary end point was the combination of all-cause mortality or hospitalization due to worsening heart failure or cardiac arrhythmias. RESULTS: TGF-β1 was independently associated with the occurrence of the primary and secondary end points. The optimal cutoff for TGF-β1 to identify the primary end point was 12.9 ng/ml (area under the curve = 0.82, p = 0.004, sensitivity 100%, and specificity 57%) and to identify the secondary end point was 30.8 ng/ml (area under the curve = 0.72, p = 0.03, sensitivity 60%, and specificity 86%). LV ejection fraction and LV end-diastolic diameter were also independent predictors of the primary and secondary endpoints, respectively. CONCLUSION: The described association between TGF-β1 and clinical outcome provides evidence towards the clinical value of TGF-β1 in Chagas disease.
BACKGROUND: Transforming growth factor-β1 (TGF-β1) may be implicated in the development of Chagas heart disease. However, the clinical value of TGF-β1 measurement is yet to be determined. METHODS: We retrospectively analyzed the outcome of 54 Chagas diseasepatients without heart failure and with left ventricular (LV) ejection fraction >45% whose TGF-β1 serum values were determined between January 1998 and December 1999. Primary end point was all-cause mortality and secondary end point was the combination of all-cause mortality or hospitalization due to worsening heart failure or cardiac arrhythmias. RESULTS: TGF-β1 was independently associated with the occurrence of the primary and secondary end points. The optimal cutoff for TGF-β1 to identify the primary end point was 12.9 ng/ml (area under the curve = 0.82, p = 0.004, sensitivity 100%, and specificity 57%) and to identify the secondary end point was 30.8 ng/ml (area under the curve = 0.72, p = 0.03, sensitivity 60%, and specificity 86%). LV ejection fraction and LV end-diastolic diameter were also independent predictors of the primary and secondary endpoints, respectively. CONCLUSION: The described association between TGF-β1 and clinical outcome provides evidence towards the clinical value of TGF-β1 in Chagas disease.
Authors: Eva H Clark; Morgan A Marks; Robert H Gilman; Antonio B Fernandez; Thomas C Crawford; Aaron M Samuels; Alicia I Hidron; Gerson Galdos-Cardenas; Gilberto Silvio Menacho-Mendez; Ricardo W Bozo-Gutierrez; Diana L Martin; Caryn Bern Journal: Am J Trop Med Hyg Date: 2014-11-10 Impact factor: 2.345
Authors: Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman Journal: Annu Rev Pathol Date: 2018-10-24 Impact factor: 23.472
Authors: Herbert B Tanowitz; Fabiana S Machado; David C Spray; Joel M Friedman; Oren S Weiss; Jose N Lora; Jyothi Nagajyothi; Diego N Moraes; Nisha Jain Garg; Maria Carmo P Nunes; Antonio Luiz P Ribeiro Journal: Expert Rev Cardiovasc Ther Date: 2015-10-23
Authors: Eduardo Ov Curvo; Roberto R Ferreira; Fabiana S Madeira; Gabriel F Alves; Mayara C Chambela; Veronica G Mendes; Luiz Henrique C Sangenis; Mariana C Waghabi; Roberto M Saraiva Journal: Mem Inst Oswaldo Cruz Date: 2018-02-19 Impact factor: 2.743